Maxim Group Upgrades Cassava Sciences (SAVA) to Buy, AFter Pharma Study Results Released
Tweet Send to a Friend
Maxim Group analyst Jason McCarthy upgraded Cassava Sciences (NASDAQ: SAVA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
